The clinical impact of frailty in transplant ineligible patients with multiple myeloma treated with bortezomib-based chemotherapy as front line therapy

被引：0

作者：

Lee, Ho Sup ^{[1
]}

Kim, Da Jung ^{[1
]}

Lee, Ji Hyun ^{[2
]}

Lee, Je-Jung ^{[3
]}

Jung, Sung-Hoon ^{[3
]}

Jo, Jae-Cheol ^{[4
]}

Lee, Yoo Jin ^{[4
]}

Shin, Ho-Jin ^{[5
]}

Lee, Won ^{[6
]}

机构：

[1] Kosin Univ, Coll Med, Busan, South Korea

[2] Dong A Univ, Coll Med, Busan, South Korea

[3] Chonnam Natl Univ, Hwasun Hosp, Hwasun Gun, Jeollanam Do, South Korea

[4] Ulsan Univ Hosp, Ulsan, South Korea

[5] Pusan Natl Univ Hosp, Busan, South Korea

[6] Busan Paik Hosp, Busan, South Korea

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

bortezomib; frailty; Multiple myeloma;

D O I：

10.1016/j.clml.2019.09.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-015

引用

页码：E11 / E12

页数：2

共 50 条

[21] The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients [J].

Shimazu, Yutaka ;

Kanda, Junya ;

Takakuwa, Teruhito ;

Onda, Yoshiyuki ;

Fukushima, Kentaro ;

Hotta, Masaaki ;

Fuchida, Shin-ichi ;

Uoshima, Nobuhiko ;

Shimura, Yuji ;

Tanaka, Hirokazu ;

Ohta, Kensuke ;

Shibayama, Hirohiko ;

Kosugi, Satoru ;

Yagi, Hideo ;

Yoshihara, Satoshi ;

Hosen, Naoki ;

Ito, Tomoki ;

Shimazaki, Chihiro ;

Matsumura, Itaru ;

Kuroda, Junya ;

Takaori-Kondo, Akifumi ;

Hino, Masayuki .

ANNALS OF HEMATOLOGY, 2024, 103 (12) :5639-5649

[22] A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma [J].

Wei, Daolin ;

Tong, Yin ;

Bai, Haitao ;

Cai, Qi ;

Gao, Yanrong ;

Wang, Chun .

ONCOTARGET, 2016, 7 (43) :70168-70174

[23] Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma [J].

Lamm, W. ;

Drach-Schauer, B. ;

Eder, S. ;

Drach, J. .

ONCOLOGY, 2013, 85 (04) :223-227

[24] Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma [J].

Sopena, Maria ;

Clavero, Estela Martin ;

Villa, Paula ;

Martinez-Lopez, Joaquin .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (03) :147-154

[25] Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving bortezomib-based therapy for multiple myeloma [J].

Zhou, Xin ;

Wang, Jing ;

Xia, Jun ;

Cheng, Feng ;

Mao, Jingjue ;

Zhu, Jianwei ;

Guo, Hongfeng .

CANCER BIOMARKERS, 2018, 22 (01) :43-48

[26] Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era [J].

Wei, Min ;

Guo, Honggang ;

Liu, Siwei ;

Xu, Fangfang ;

Zhang, Yin ;

Shi, Jie ;

Xu, Zhiwei ;

Chen, Yuqing .

MEDICINE, 2021, 100 (41) :E27521

[27] Bortezomib-based regimens for primary multiple myeloma patients in China: from 2006 to 2018 [J].

Cai, Zhen ;

He, Jingsong ;

He, Donghua ;

Han, Xiaoyan ;

Zheng, Gaofeng ;

Zhao, Yi ;

Yang, Yang ;

Wu, Wenjun ;

Huang, He ;

Fu, Jiaping ;

Shou, Lihong ;

Kong, Hongwei .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) :E202-E202

[28] Superior myeloma response with bortezomib-based regimen in multiple myeloma patients with renal impairment [J].

Bao, Li ;

Lu, Jin ;

Wang, Shihua ;

Huang, Xiaojun .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03) :6200-6209

[29] Impact on efficacy of the dose and schedule of bortezomib in Transplant-Ineligible Newly Diagnosed Multiple Myeloma [J].

Ibarra, Gladys ;

Abril, Laura ;

Pena, Marta ;

Oriol, Albert .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) :E235-E235

[30] Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens - pilot study [J].

Pula, Anna ;

Robak, Tadeusz ;

Drozdz, Izabela ;

Stawiski, Konrad ;

Rycerz, Aleksander ;

Misiewicz, Malgorzata ;

Robak, Pawel .

LEUKEMIA & LYMPHOMA, 2024, 65 (02) :257-264

← 1 2 3 4 5 →